In a recent issue of Cancer Discovery, Bleve and colleagues point to cholesterol-driven RORγ activation as the molecular trigger of myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) expansion, resulting in defective antitumor response and disease progression. Here, RORC is linked to neoplasm.